Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model.

Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting.

Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa ST175 in a Hollow-Fiber Infection Model.